A carregar...
Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
Background: Prostate cancer is the second most frequently diagnosed malignancy worldwide. Here, the cytotoxic and antimetastatic effects of a new HDAC6/8 inhibitor, LASSBio-1911, and a new dual-PI3K/HDAC6 inhibitor, LASSBio-2208, were evaluated against PC3 prostate cancer cell line. Methods: A MTT a...
Na minha lista:
| Publicado no: | Pharmaceuticals (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143108/ https://ncbi.nlm.nih.gov/pubmed/33919077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14050387 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|